Adverse Drug Reaction vs Care Complication: Response to "Use of Colony-Stimulating Factors in Patients With Systemic Lupus Erythematous".

Competing Interests: Declaration of Conflicting InterestsThe author(s) declared following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CR is an employee of and has stock options for Partner Therapeutics, Inc., the manufacturer of sargramostim. ER was an employee of Partner Therapeutics, Inc. at the time of initial submission of this Letter and has stock options.